Tag Archives: Cayman Islands

Aedes aegypti OX513A

http://www.oxitec.com/health/our-products/aedes-agypti-ox513a/
Product profile
OX513A is a bisex RIDL strain. Males are released to mate with wild females. The progeny of such matings die as late larvae or pupae. Continual releases of sufficient numbers of RIDL males will reduce the target population to below the level needed to transmit disease. The late lethality means that RIDL larvae compete with wild-type larvae for resources,adding to the overall effectiveness of control. Before release, male and female pupae are separated mechanically, exploiting the fact that they are naturally significantly different in size. The strain contains the DsRed marker which is clearly visible in larvae, a useful tool for quality control in production and effective monitoring in the field. OX513A is available in Asian and Latin American genetic backgrounds.

Status
OX513A has regulatory approvals for import and contained testing in Brazil, Cayman Islands, France, India, Malaysia, Singapore, Thailand, USA and Vietnam. Open field trials have taken place in both Grand Cayman and Malaysia, and are currently also underway in Brazil.

Advertisements

Oxitec (GM Mosqitoes) – Our Team

Oxitec Ltd. was founded in 2002 and is based in Oxford, United Kingdom. As of September 8, 2015, Oxitec Ltd. operates as a subsidiary of Intrexon Corporation.

http://www.oxitec.com/who-we-are/our-team/

Hadyn Parry, Chief Executive Officer

Hadyn ParryHadyn has an extensive background in the Life Science sector. During his fifteen-year career at Zeneca/Syngenta he held various positions, including General Manager of Zeneca Plant Sciences and European Director and Global Head of R&D for Advanta, one of the world’s largest seed companies. More recently he was CEO of MNL Pharmaceuticals, a company that was focused on pioneering a novel approach in immunology. Hadyn is also Chairman of Help For Heroes, a charity founded in 2007 to support wounded British soldiers.

Simon Warner, Chief Scientific Officer

Simon WarnerSimon has eighteen years of global commercial experience in biotechnology R&D in various roles at Syngenta in the United Kingdom and the United States, leading collaborative programs and delivering biotechnology products in crops for feed and fuel. Additionally, whilst at Syngenta he also worked as the R&D lead on technology acquisition on various agreements. Immediately prior to joining Oxitec, he was Senior Director of Research and Development Programs at Sapphire Energy, a start-up making algae based fuel, based in San Diego, California. Simon has a BSc in biochemistry from UCL and PhD in plant molecular biology from the University of Leicester.

Bill Fleming, Chief Financial Officer

Bill Fleming Bill joins us from Bayer Healthcare having held senior finance positions in Europe and the USA. He has a law degree from Cambridge University and is a qualified ACMA. Previously, Bill served as European Finance Director for Visible Genetics, a pioneering company in the field of nucleic acid diagnostics.

Camilla Beech, Regulatory Affairs Manager

Camilla BeechCamilla has extensive international experience in the regulation of biotechnology products and crops. She obtained commercial food approval in the UK for the first GM crop in Europe, and obtained registrations for numerous biotechnology crops in Africa, Asia and the Americas. She advised the Humanitarian Board for Golden Rice on regulatory matters (1997 to 2004), and was a member of both US (BIO) and European Inter-industry groups (EUROPABIO) on The Cartagena Biosafety Protocol, Convention on Biological Diversity and Plant made Pharmaceuticals. Her most recent post was International Regulatory Manager for Syngenta Biotechnology Inc., based in San Diego, California.

Glen Slade, Head of Business Development

Glen SladeGlen has worked in agribusiness since 1998 when he joined Zeneca Agrochemicals as Head of Strategy. There he championed the role of biotechnology in integrated crop solutions, leading to the merger that formed Syngenta. He then worked in independent consulting roles addressing high profile marketing and strategy projects for Syngenta, Arysta and other agribusiness firms. In parallel to this work, Glen set up and ran two IT-related companies. He has a degree from Cambridge University and an MBA from Insead.

Hadyn Parry: Re-engineering mosquitos to fight disease

Published on 3 Jan 2013
In a single year, there are 200-300 million cases of malaria and 50-100 million cases of dengue fever worldwide. So: Why haven’t we found a way to effectively kill mosquitoes yet? Hadyn Parry presents a fascinating solution: genetically engineering male mosquitoes to make them sterile, and releasing the insects into the wild, to cut down on disease-carrying species.
TED Talk Link

Transcript:
9:27
“And that’s exactly where we are. So this is technology that was developed in Oxford University a few years ago. The company itself, Oxitec, we’ve been working for the last 10 years, very much on a sort of similar development pathway that you’d get with a pharmaceutical company. So about 10 years of internal evaluation, testing, to get this to a state where we think it’s actually ready. And then we’ve gone out into the big outdoors, always with local community consent, always with the necessary permits. So we’ve done field trials now in the Cayman Islands, a small one in Malaysia, and two more now in Brazil…

We can produce them, in a space a bit more than this red carpet, I can produce about 20 million a week. We can transport them around the world. It’s not very expensive, because it’s a coffee cup — something the size of a coffee cup will hold about three million eggs. So freight costs aren’t our biggest problem. (Laughter) So we’ve got that. You could call it a mosquito factory. And for Brazil, where we’ve been doing some trials, the Brazilian government themselves have now built their own mosquito factory, far bigger than ours, and we’ll use that for scaling up in Brazil.